Series: Landmark Trials in Endocrinology & Metabolism | Study #31
Category: Lipids & Statins · Cardiovascular Outcomes | Design: Multicentre, double-blind, placebo-controlled RCT | n: 20,536 | Follow-up: 5 years (scheduled)
📋 Summary
Authors: Heart Protection Study Collaborative Group
Journal: Lancet 2002;360:7–22 | DOI: 10.1016/S0140-6736(02)09327-3
The Heart Protection Study randomly allocated 20,536 UK adults aged 40–80 years with coronary disease, other occlusive arterial disease, or diabetes to receive simvastatin 40 mg daily or matching placebo, with an average compliance of 85% in the simvastatin group and 17% non-study statin use in the placebo group. The two thirds compliance-adjusted difference in LDL-cholesterol between groups was approximately 1.0 mmol/L. All-cause mortality was significantly reduced in the simvastatin group: 12.9% (1,328 deaths) versus 14.7% (1,507 deaths) in the placebo group (p=0.0003), a relative reduction of approximately 13% on an intention-to-treat basis. The coronary death rate was reduced by 18% (SE 5; p=0.0005). First major vascular events were reduced by 24% (19 to 28%; p<0.0001) across all categories: non-fatal MI or coronary death (8.7% vs 11.8%; p<0.0001), non-fatal or fatal stroke (4.3% vs 5.7%; p<0.0001), and coronary or non-coronary revascularisation (9.1% vs 11.7%; p<0.0001). The proportional reduction in major vascular events was consistent across all pre-specified subgroups, including patients without diagnosed coronary disease, patients with diabetes, women, patients aged above 70, and patients with baseline LDL-cholesterol below 3.0 mmol/L or total cholesterol below 5.0 mmol/L. The annual excess risk of myopathy was 0.01%. No significant adverse effects on cancer incidence were observed.
📊 Key Findings
<figure class="wp-block-table">
| Outcome | Simvastatin | Placebo | Effect Size |
|---|---|---|---|
| All-cause mortality | 12.9% | 14.7% | p=0.0003 · ~13% ITT reduction |
| Coronary death | 5.7% | 6.9% | 18% reduction (SE 5) · p=0.0005 |
| Any major vascular event | 19.8% | 25.2% | 24% reduction (19–28%) · p<0.0001 |
| Non-fatal MI or coronary death | 8.7% | 11.8% | 27% reduction · p<0.0001 |
| Stroke | 4.3% | 5.7% | 25% reduction · p<0.0001 |
| Subgroup: baseline LDL <3.0 mmol/L | <td colspan="2">Consistent benefit maintainedNo threshold LDL below which benefit disappears | ||
| Subgroup: diabetes (no coronary disease) | <td colspan="2">Significant benefitEstablished diabetes-specific statin indication | ||
| Myopathy risk | <td colspan="2">0.01% per yearVery low safety risk confirmed |
💬 Expert Commentary
HPS was the most important statin trial of its era because it answered a question that 4S and WOSCOPS, despite their landmark results, had left open: does statin therapy benefit all high-risk patients regardless of baseline LDL-cholesterol level, or only those whose LDL exceeds a certain threshold? The finding that the proportional reduction in major vascular events was statistically significant and quantitatively similar in patients with baseline LDL below 3.0 mmol/L as in those with higher LDL was genuinely novel and had immediate guideline consequences. It removed the concept of a cholesterol threshold for treatment and replaced it with the concept of cardiovascular risk as the primary treatment criterion — a shift that led to the modern risk-based guidelines that focus on absolute cardiovascular risk rather than lipid levels alone as the trigger for therapy.
The HPS diabetes subgroup — patients with diabetes but no diagnosed coronary disease — demonstrated a significant vascular event reduction with simvastatin, directly establishing the evidence base for routine statin use in all patients with diabetes above a certain age regardless of baseline LDL. The CARDS trial (Study #32) subsequently provided confirmatory dedicated evidence for primary prevention in type 2 diabetes, but HPS, with its larger numbers and broader population, was the first definitive demonstration of this specific benefit. HPS also confirmed the safety of long-term statin therapy at scale: with over 20,000 patients, five years of follow-up, and systematic cancer surveillance, the absence of any excess non-vascular mortality and the extremely low myopathy incidence (0.01% per year) provided reassurance that has supported the global expansion of statin prescribing ever since.
Limitations: Compliance-adjusted analyses, while providing a more accurate estimate of per-protocol drug effect, introduce some analytical complexity. The 17% non-study statin use in the placebo group dilutes the treatment contrast. The study focused on simvastatin 40 mg and findings may not be fully applicable to other statins or doses. The study was funded by the MRC and BHF.
<blockquote class="wp-block-quote">
🔑 BOTTOM LINE
HPS demonstrated that simvastatin reduces major vascular events by 24% across all high-risk patients regardless of baseline LDL-cholesterol level, including those with diabetes without established coronary disease and those with baseline LDL below 3.0 mmol/L, eliminating the concept of a cholesterol threshold for treatment and establishing absolute cardiovascular risk as the primary criterion for statin therapy.
⭐ Clinical Impact Rating: ●●●●● Practice-defining
Next in the series: Study #32 CARDS: Atorvastatin for Primary Prevention in Type 2 Diabetes — No LDL Threshold Required
